Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | The benefits of immune reconstitution therapy in MS

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the use of immune reconstitution therapy or continuous immunosuppression for the management of multiple sclerosis (MS) patients. Most disease-modifying therapies available for managing active MS depend on continuous drug intake for maintained efficacy. By contrast, immune reconstitution therapies, such as alemtuzumab and cladribine, can provide long-term suppression of MS disease activity without the need for continuous treatment. Besides reducing treatment burden, immune reconstitution therapy has a lower potential for long-term continuous immunosuppression to promote malignancy. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


C Oreja-Guevara has received honoraria for speaking and serving on advisory boards from Biogen Idec., F. Hoffmann-La Roche Ltd, Sanofi-Genzyme, Merck, Janssen, BMS, Novartis, and Teva.